CTMX

CytomX Therapeutics Inc

2.19

Nov 06 • 3:59 PM ET +0.05 (2.34%)

2.19

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Nov 05, 6:53 PMCytomX advances Varseta-M toward 1H27 registrational trial, extends cash runway to 2H28

Peers: JANX STRO IMNM VIR XLO ZYME PYXS MGNX BCYC ADCT

| Held by: VTI XBI IWM VXF IBB VTWO IWO IWN VHT IWC

Scroll to Statements

Index	RUT
Market Cap	477.43M
Enterprise Value	132.92M
Income	-88.42M
Sales	14.03M
Book/sh	1.31
Cash/sh	1.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	69
IPO	Oct 08, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	34.03
P/B	1.68
P/C	1.37
P/FCF	-
EV/EBITDA	-
EV/Sales	9.47
Quick Ratio	7.82
Current Ratio	7.82
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-0.46
EPS next Y	-0.50
EPS next Q	-0.08
EPS this Y	-159.53%
EPS next Y	-28.39%
EPS next 5Y	-
EPS past 3/5Y	53.93% 27.00%
Sales past 3/5Y	12.75% -5.36%
EPS Y/Y TTM	-210.45%
Sales Y/Y TTM	-87.66%
EPS Q/Q	-5.92%
Sales Q/Q	-71.69%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-25.17% -83.73%

Insider Own	18.91%
Insider Trans	-0.00%
Inst Own	93.79%
Inst Trans	2.25%
ROA	-32.67%
ROE	-43.55%
ROIC	-29.58%
Gross Margin	91.28%
Oper. Margin	-676.46%
Profit Margin	-630.38%
SMA20	-5.38%
SMA50	-19.32%
SMA200	-42.36%
Trades

Shs Outstand	217.95M
Shs Float	176.77M
Short Float	24.21%
Short Ratio	11.63
Short Interest	42.79M
52W High	8.21 -73.33%
52W Low	2.11 3.79%
Volatility	9.26% 7.45%
ATR (14)	0.17
RSI (14)	40.99
Beta	2.25
Rel Volume	0.74
Avg Volume	3.68M
Volume	2,727,242

Perf Week	-6.41%
Perf Month	-11.34%
Perf Quarter	-36.34%
Perf Half Y	-44.97%
Perf YTD	-48.59%
Perf Year	-47.73%
Perf 3Y	72.44%
Perf 5Y	-66.82%
Perf 10Y	-80.02%
Recom	1.12
Target Price	12.25
Prev Close	2.14
Price	2.19
Change %	2.34%

Consensus

Strong Buy

Avg. Price Target

$12.25

Implied Upside

+459.4%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 19, 2026	Initiated	WWolfe Research	Outperform	$6	+174.0%
Mar 16, 2026	Upgrade	JJP Morgan	Neutral → Overweight	$12	+447.9%
Jan 20, 2026	Initiated	GGuggenheim	Buy	$10	+356.6%
Sep 22, 2025	Initiated	CCantor Fitzgerald	Overweight	$6	+174.0%
Sep 17, 2025	Resumed	BBarclays	Overweight	$3.50	+59.8%
Jul 31, 2025	Initiated	OOppenheimer	Outperform	$7	+219.6%
May 15, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$5	+128.3%
Apr 14, 2025	Resumed	PPiper Sandler	Overweight	$3.25 → $2.50	+14.2%
May 28, 2024	Upgrade	PPiper Sandler	Neutral → Overweight	$2.25 → $3.50	+59.8%
May 09, 2024	Upgrade	WWedbush	Neutral → Outperform	$8	+265.3%
May 06, 2024	Upgrade	JJefferies	Hold → Buy	$2.50 → $8	+265.3%
Apr 22, 2024	Upgrade	JJP Morgan	Underweight → Neutral
Nov 14, 2022	Downgrade	BBMO Capital Markets	Outperform → Market Perform	$3 → $2.60	+18.7%
Jul 07, 2022	Downgrade	WWedbush	Outperform → Neutral	$6 → $2	-8.7%
Jul 07, 2022	Downgrade	PPiper Sandler	Overweight → Neutral	$10 → $1.50	-31.5%
Jul 07, 2022	Downgrade	MMizuho	Buy → Neutral	$16 → $4	+82.6%
Jul 07, 2022	Downgrade	JJefferies	Buy → Hold	$12 → $2	-8.7%
Jun 24, 2022	Initiated	BBMO Capital Markets	Outperform	$9	+311.0%
Jan 18, 2022	Upgrade	BBarclays	Underweight → Overweight	$7	+219.6%
Nov 15, 2021	Initiated	BBTIG Research	Buy	$16	+630.6%

Nov-05-26 09:18PM	CytomX Matches On EPS, But Varseta-M Data Slips To 2027 Shift The Burden To January (Earnings Whispers) -8.94%
04:31PM	CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press)
04:15PM	CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-26 08:00AM	CytomX Therapeutics to Present at Upcoming November Investor Conferences (GlobeNewswire)
Oct-29-26 12:10PM	CytomX Stock Near Lows As Investors Seek Proof Varsetta M Is On Pivotal Track (Earnings Whispers)
08:00AM	Loading…
08:00AM	CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
Sep-01-26 08:00AM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) +9.23%
Aug-27-26 08:00AM	CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) (GlobeNewswire)
Aug-07-26 01:03AM	CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... (GuruFocus.com)
Aug-06-26 05:04PM	CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:15PM	CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-26 08:00AM	CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer (GlobeNewswire)
Jul-30-26 08:00AM	CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-27-26 08:00AM	CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors (GlobeNewswire)
Jul-06-26 11:19AM	A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
08:00AM	Loading…
Jun-03-26 08:00AM	CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer (GlobeNewswire)
May-21-26 08:00AM	CytomX Therapeutics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-18-26 08:00AM	CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs (GlobeNewswire)
May-07-26 05:32PM	CytomX Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:15PM	CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-26 08:00AM	CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Mar-17-26 10:46PM	CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -19.26% -19.27%
Mar-16-26 04:04PM	CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +44.23%
03:00PM	CytomX Therapeutics Inc (CTMX) Q4 2025 Earnings Call Highlights: Promising Phase 1 Data and ... (GuruFocus.com)
08:27AM	CytomX surges on positive data for masked ADC in colorectal cancer (BioPharma Dive)
07:25AM	CytomX Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	CytomX's Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer (GlobeNewswire)
Mar-05-26 05:15PM	Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.92%
Mar-04-26 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 (GlobeNewswire) +5.41%
12:15PM	Loading…
Feb-26-26 12:15PM	NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates (Zacks) -5.19%
Feb-24-26 09:55PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.25%
Feb-17-26 05:00AM	Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating (Insider Monkey)
Feb-12-26 02:48AM	CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts (MarketBeat)
Feb-04-26 05:55PM	Qiagen (QGEN) Meets Q4 Earnings Estimates (Zacks) -6.59% -7.58%
08:00AM	CytomX Therapeutics to Present at Upcoming February Conferences (GlobeNewswire)
Feb-02-26 09:37AM	Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) (Insider Monkey) +7.03%
Jan-30-26 06:40AM	Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-21-26 06:05AM	Qiagen (QGEN) Soars 16.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-19-26 09:17AM	CytomX Stock Rises 31% in a Month: Here's What You Should Know (Zacks)
Jan-08-26 08:00AM	CytomX Therapeutics Announces Business Update and Company Milestones for 2026 (GlobeNewswire)
Jan-07-26 04:45AM	Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) (Insider Monkey)
Dec-21-25 07:31AM	Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress (Insider Monkey)
Nov-25-25 08:00AM	CytomX Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire)
Nov-13-25 08:00AM	CytomX Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -8.75%
Nov-07-25 12:09AM	CytomX Therapeutics Inc (CTMX) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline ... (GuruFocus.com) -13.60%
Nov-06-25 07:00PM	CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:53PM	CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 09:15AM	CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-30-25 11:29PM	Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT (Insider Monkey) +7.21%
08:00AM	CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-27-25 05:30PM	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates (Zacks)
Oct-20-25 04:05PM	CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer (GlobeNewswire) +16.87%
Sep-26-25 08:08AM	Why CytomX Therapeutics Stock Was Skyrocketing This Week (Motley Fool)
Aug-28-25 08:00AM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-15-25 07:46AM	CytomX to continue Phase I ADC trial despite patient death (Clinical Trials Arena) +8.52%
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:00AM	CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study (GlobeNewswire)
Aug-08-25 03:40AM	CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +11.90%
Aug-07-25 05:25PM	CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 (Zacks)
04:27PM	CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 08:00AM	CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire) -5.60%
Jul-25-25 12:09PM	CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate (Insider Monkey)
Jul-09-25 08:30AM	Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers (PR Newswire)
May-29-25 08:00AM	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-25 08:00AM	CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma (GlobeNewswire)
May-13-25 01:58AM	Q1 2025 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +17.37%
May-12-25 07:25AM	CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates (Zacks) +129.43%
06:50AM	CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:22AM	CytomX Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:15AM	CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
06:15AM	CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) (GlobeNewswire)
May-09-25 05:40PM	SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.83%
09:46AM	CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-08-25 05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +13.48%
May-05-25 12:12PM	ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? (Zacks) +19.85%
09:54AM	Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock? (Zacks)
08:00AM	CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire)
07:12AM	Novavax to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
May-02-25 01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks) +5.90%
Apr-30-25 05:50PM	Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +14.23%
Apr-29-25 11:59AM	Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) -7.95%
07:51AM	Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
Apr-28-25 04:00PM	CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting (GlobeNewswire)
09:14AM	GSK to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
09:04AM	Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-25-25 11:59AM	CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) -7.29%
11:57AM	Can Moderna Keep the Beat Streak Alive This Earnings Season? (Zacks)
11:16AM	Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? (Zacks)
10:14AM	CytomX Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
09:25AM	Beam Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-24-25 02:20PM	Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut (Zacks)
06:31AM	Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips (Zacks)
Apr-23-25 09:25AM	Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
07:50AM	Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know (Zacks)
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 07:36AM	Viking Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) +14.31%
Apr-16-25 07:32AM	SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ogden Christopher	Chief Financial Officer	Jun 15 '26	Sale	3.05	1,624	4,953	295,324	Jun 17 06:38 PM
Chu Yu-Waye	Chief Medical Officer	Mar 17 '26	Sale	6.42	21,279	136,675	189,446	Mar 19 06:41 PM
McCarthy Sean A.	CEO	Mar 17 '26	Sale	6.42	118,969	764,138	1,078,922	Mar 19 06:35 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Mar 17 '26	Sale	6.42	31,492	202,273	300,760	Mar 19 06:25 PM
Ogden Christopher	Chief Financial Officer	Mar 17 '26	Sale	6.42	19,323	124,112	296,948	Mar 19 06:21 PM

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies to address unmet need in oncology. The firm focuses on the field of antibody masking technologies through the development of its Probody therapeutic platform. The company was founded by Frederick W. Gluck, Nancy E. Stagliano, and Patrick S. Daugherty in February 2008 and is headquartered in South San Francisco, CA.

Chairman & CEODr. Sean A. McCarthy DPHIL

SVPMr. Christopher W. Ogden

Chief Business Officer & Senior VPMs. Rachael Lester

Senior VP & Chief Scientific OfficerDr. Marcia P. Belvin Ph.D.

Chief Legal OfficerMs. Alejandra Veronica Carvajal J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTMX

CytomX Therapeutics Inc

Upgrade your Finviz experience